Novo's CagriSema delivers 25% weight loss in women across menopause stages
Start here
At The Menopause Society 2026 annual meeting, Novo Nordisk presented a post hoc analysis of its Phase 3 REDEFINE 1 trial focused on women. Among 2,309 women treated with CagriSema for 68 weeks, average weight loss was 25% of body weight. The effect was strongest in premenopausal women at 26.7%, compared with 24.8% in perimenopausal and 23.1% in postmenopausal women, indicating that younger patients drove the overall result while all groups still achieved substantial reductions. The findings add menopause-stage detail to the REDEFINE 1 dataset, though the analysis is post hoc and further data on CagriSema's broader profile and regulatory trajectory remain outstanding.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- BioSpacePickNovo’s CagriSema achieves 25% weight loss in women, driven by younger patients
Novo Nordisk presented a post hoc analysis of the Phase 3 REDEFINE 1 trial at The Menopause Society 2026 annual meeting. Among 2,309 women, CagriSema produced mean weight loss of 25% at 68 weeks; stratified by menopausal stage, weight loss was 26.7% in premenopausal, 24.8% in perimenopausal, and 23.1% in postmenopausal women, versus 1.7% to 2.6% on placebo.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 21:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.